CureSearch for Children's Cancer funds and supportstargeted and innovative children's cancer research with measurableresults, and is the authoritative source of information and resourcesfor all those affected by children's cancer.
On January 1, 2011, Peter C. Adamson, MD assumed the role of Chair of the Children’s Oncology Group (COG), a National Cancer Institute supported consortium of more than 210 centers across North America, Australia, New Zealand and parts of Europe. The COG conducts clinical-translational research including large-scale clinical trials in children with cancer. Dr. Adamson is also Chief of the Division of Clinical Pharmacology & Therapeutics at The Children's Hospital of Philadelphia, having served as its Director for Clinical & Translational Research through 2009.
Dr. Adamson begins this role at a time when new breakthroughs in the understanding of childhood cancer appear to be occurring at a pace faster than ever. In addition to overall cure rates now approaching 80%, childhood cancer researchers are beginning to use their increased knowledge of the genetic changes that arise in cancer cells to develop medications that better target the cancer and potentially have fewer side effects. As this type of work becomes more and more refined, the goal will be to develop more specific treatments not only each subtype of cancer, but also eventually for individual patients.
In addition to this exciting work, Dr. Adamson plans to streamline the development of the most promising new treatments, devote increased resources to those cancers where progress has been more limited, and support research efforts that aim to minimize the long-term effects of treatment that can occur in survivors of childhood cancer.
While serving as chair, Dr. Adamson will continue to have a role overseeing his laboratory, which is focused on the development of new drugs for childhood cancer, including the conduct of initial clinical trials of new therapies. In addition, he will continue to care for children undergoing cancer treatment, and supervise and teach fellows, residents and medical students in the field of pediatric oncology.
Dr. Adamson will serve a five-year term and can be elected to a second term after that. He is only the second person to serve as Chair of the COG – the first was Gregory Reaman, MD who helped found the organization ten years ago.
About Peter C. Adamson, MDDr. Adamson, a Professor of Pediatrics and Pharmacology at the University of Pennsylvania School of Medicine, is Chief of the Division of Clinical Pharmacology and Therapeutics at The Children’s Hospital of Philadelphia (CHOP). Dr. Adamson is Board Certified in Pediatric Hematology/Oncology and in Clinical Pharmacology. He is an internationally recognized leader in pediatric cancer drug development, having served until 2008 as Chair of the COG’s Developmental Therapeutics Programs and Principal Investigator of its phase 1 consortium. Prior to becoming Chair of the COG, he served as Director for Clinical and Translational Research at CHOP, including being the co-Director of the University of Pennsylvania – CHOP Clinical Translational Science Award (CTSA). Dr. Adamson’s past experience includes being Program Director of the General Clinical Research Center (GCRC) and Principal Investigator of the NICHD funded Pediatric Pharmacology Research Unit (PPRU). His laboratory focuses on the clinical pharmacology of new drugs for childhood cancer using an integrated approach that incorporates preclinical studies in model systems and clinical trials with pharmacokinetic-pharmacodynamic-pharmacogenetic studies in pediatric patients. Dr. Adamson serves on key national advisory committees, including the NCI’s Investigational Drug Steering Committee and the NCI Director’s Clinical Trials Advisory Committee.
Shelby HammondCommunications Manager Email Shelby(240) 235-2205